Search Results

City of Hope and DELFI Diagnostics, Inc. announced a collaboration to utilize DELFI’s FirstLook Lung, a blood-based lung cancer screening test, in a City of Hope clinical study to help improve screening rates in underserved communities in Los Angeles County.

April 2, 2024

·

7 min read

BioCapital

DELFI Diagnostics to Present at American Association for Cancer Research Annual Meeting

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced multiple upcoming poster and oral presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, from April 5-10, 2024.

April 1, 2024

·

4 min read

Business

DELFI Diagnostics Appoints Susan Tousi as New Chief Executive Officer

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, announced the appointment of Susan Tousi as Chief Executive Officer.

January 5, 2024

·

4 min read

BioCapital

DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced availability of the company’s fragmentome-based research use only (RUO) cancer monitoring assay.

February 1, 2024

·

2 min read

BioCapital

DELFI Diagnostics Supports Proposed Legislation to Allow CMS to Review New Blood-Based Screening Tests for Lung Cancer

DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced support for the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).

December 13, 2023

·

5 min read